In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity.
Using a clonogenic cell survival assay, the chemosensitivity of four recently established cervix carcinoma cell lines to four drugs used in the treatment of this disease (bleomycin, cisplatin, etoposide and methotrexate) has been determined. Exposure was for 1 h except for methotrexate where 24 h was used. Results showed that, on a molar basis, bleomycin was most cytotoxic against each cell line (doses to produce 10% cell survival from 10 to 40 mciroM). However, if the clinical area under the curve (AUC) values are taken into consideration, the cell lines appeared to be relatively resistant to cisplatin (surviving fraction range of 0.9-0.6) and methotrexate but sensitive to bleomycin and etoposide (surviving fraction range of 0.18-0.012). Among this small group of lines, there was some evidence to suggest a positive correlation between chemo- and radiosensitivity; the HX/151c line was significantly more radiosensitive than the other three lines (P = 0.03) and clearly more chemosensitive, particularly against bleomycin (correlation coefficient of 0.81) and etoposide (correlation coefficient of 0.80).
Kelland
L R
LR
Drug Development Section, Institute of Cancer Research, Sutton, Surrey, U.K.
Tonkin
K S
KS
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002460:Cell Line; D002945:Cisplatin / Q000627:therapeutic use; D004361:Drug Tolerance; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011836:Radiation Tolerance; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000528:radiation effects; D014410:Tumor Stem Cell Assay; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin; D008727:Methotrexate